about
Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccineTranscriptomic profiling facilitates classification of response to influenza challenge.Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.Incidental diagnosis in healthy clinical trial subjectsChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.Development, impact and outcomes of the Hull Bacteraemia Service.Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.Healthcare associated discitis in the era of antimicrobial resistance.Prescribing at the coalface in the era of antimicrobial resistance.Baseline factors predicting the duration of intravenous antibiotic therapy for cellulitis in an outpatient setting.Oral voriconazole for invasive fungal skull base infection.Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial.An unusual pathogen in ambulatory care: two cases of Scedosporium soft tissue infections presenting as "unresponsive cellulitis".Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivityBloodstream infection: Bacteraemia service model of infection care.Empiric albendazole therapy and new onset seizures--a cautionary note.Severity assessment of influenza virus infection in secondary care.Painful lymphadenopathy due to silicone breast implant rupture following extensive global air travel.Fever as nature's engine. Some clinical data.HIV seroconversion complicated by Mycobacterium kansasii infection68 Consecutive patients assessed for COVID-19 infection; experience from a UK regional infectious disease unitEscherichia coli bloodstream infection outcomes and preventability: a six-month prospective observational studyHospitalised adults with pneumonia are frequently misclassified as another diagnosisRare and unusual case of hepatic and disseminated tuberculosis in an immunocompetent patient
P50
Q30416005-4314E46F-82DB-4E5E-B856-9333C64F005CQ33974904-072B9B6B-58C8-48F9-B3B6-4315A74C3B9BQ34464975-6381B197-43D9-47FE-AAA9-68F9660C407BQ34699088-8F4B81F5-BE0D-4019-BB24-9A8A77C9B0FBQ34712767-4ACA2ED3-9A29-44F5-84BF-7EE61ADCAFE9Q34798503-5F7FA542-144C-4CF1-93D8-E1572C30DE83Q36014866-244A1041-55A1-4F58-BBCA-725254541505Q36301976-C2A703B0-7098-4FD6-AE85-BFAC53B134ACQ36460499-0D3AFD9E-4B4D-4317-8048-918A475D1DD9Q37275048-EA1A4D82-AD80-4AF0-924E-012FC8255936Q38939096-826977EF-38A3-440D-8DFB-FFB078FC9E73Q39179650-1EF572A2-9288-4E53-8CE2-F7CD8F5817A9Q39179657-C0739AC3-EF65-440A-ABDF-799619C37BD4Q39179675-2BC26CF8-3B98-492E-AFA2-A6B804B839AEQ39340573-8A3C73BD-CE6C-4DCE-BF94-1B08BC7D0E55Q40061885-FF5482FC-CAAB-417E-8907-4BABDDC1E2BFQ40605312-D852FC3B-CB72-4681-99CA-588DF6E9D266Q42069334-8FDED049-0D31-40C8-94C5-2B9DA371CBCBQ43072871-31E86AB2-51F0-4CEB-BB56-74FA69536CD4Q43162903-D5BF5B7D-F640-457A-9098-2FA9EDCEA5F3Q45361390-D70B4DD8-53E8-432B-B4B4-557A9A91BFBBQ50194004-E1241F42-4771-45A0-88E4-AF677FACAFA5Q54630830-3E487E2D-18E1-478C-AA87-292F1BCCA8F2Q57195165-D1E70672-DC7A-4A77-B773-5C2056A4A770Q88975908-51E3DC11-3302-40CC-A77E-3AA700C4DD21Q92293461-32D4A6E6-A9A5-4AB6-9D46-A4090E7D0D14Q92951053-09852F85-C3B6-4BC4-9951-7B29DF884026Q92962435-78BF71F6-4E46-4AFE-BAEB-8D404119CE01
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrick Lillie
@ast
Patrick Lillie
@en
Patrick Lillie
@es
Patrick Lillie
@nl
Patrick Lillie
@sl
type
label
Patrick Lillie
@ast
Patrick Lillie
@en
Patrick Lillie
@es
Patrick Lillie
@nl
Patrick Lillie
@sl
prefLabel
Patrick Lillie
@ast
Patrick Lillie
@en
Patrick Lillie
@es
Patrick Lillie
@nl
Patrick Lillie
@sl
P106
P21
P31
P496
0000-0002-4811-4774